Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Pliant Therapeutics, Inc. PLRX

Set alert

Price alert · PLRX

All alert types
0.84 USD -0.02 -2.29%

At close · Nov 2

0.84 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
0.84 × 2
Ask
0.85 × 2
0.8388 Day range 0.8554
0.83 52-week range 1.82
YTD
-31.21%
1 year
-50.05%
Open
0.85
Prev close
0.8589
Mkt cap
51.96M
Vol
385.68K
Avg vol
396.90K
EPS
-1.50
P/E
0.00
Div yield
0.00%
More statistics
Low
0.8388
High
0.8554
Forward P/E
-3.32
Beta
1.09
Short ratio
15.30
Inst. own
111.96%
Dividend
0.00
Ex-div date
Earnings
Aug 7, 2024
50-d avg
14.08
200-d avg
13.14
1y target
40.18

3M chart

Chart tools
Interval
1m5m15m30m

Signals (15)
NameDateAgo
RSI: OversoldOct 14, 20262 weeks ago
SMA: BearishSep 25, 20261 month ago
SMA: BearishSep 25, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BearishSep 18, 20261 month ago
SMA: BullishSep 17, 20261 month ago
SMA: BullishSep 17, 20261 month ago
SMA: BearishSep 16, 20261 month ago
SMA: BearishSep 16, 20261 month ago
MACD: Sell SignalSep 15, 20261 month ago
MACD: Buy SignalSep 11, 20261 month ago
MACD: Sell SignalSep 10, 20261 month ago
SMA: BullishAug 18, 20262 months ago
SMA: BullishAug 17, 20262 months ago
MACD: Buy SignalAug 12, 20262 months ago

Analyst view

Consensus: none

Price target (mean) 40.18 +4688.1% upside
Target (low)
32.00
Target (mean)
40.18
Target (high)
47.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
  • Strong buy5
  • Buy8
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 13
  • 1 month ago 13
  • 2 months ago 13

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

PLRX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.97688-1.02 – -0.92-0.69-41.6%83.33K0.0%9
Next quarter-0.956-1.01 – -0.86-0.78-22.6%333.33K0.0%5
Current year-3.63-3.68 – -3.57-2.75-31.9%83.33K-94.7%10
Next year-3.94-4.96 – -3.11-3.63-8.5%5.75M+6800.3%11

Upgrades and downgrades

The latest rating changes

PLRX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 8, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 13, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 12, 2024HC Wainwright & Co.MaintainedBuyBuy
Aug 8, 2024Cantor FitzgeraldReiterated—Overweight
Aug 8, 2024OppenheimerMaintainedOutperformOutperform
Aug 8, 2024NeedhamReiteratedBuyBuy
Jul 16, 2024NeedhamReiteratedBuyBuy
Jul 16, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jun 7, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 7, 2024CitigroupMaintainedBuyBuy
May 7, 2024RBC CapitalMaintainedOutperformOutperform
May 7, 2024OppenheimerReiteratedOutperformOutperform
May 7, 2024NeedhamReiteratedBuyBuy
May 7, 2024HC Wainwright & Co.ReiteratedBuyBuy
Apr 10, 2024NeedhamReiteratedBuyBuy
Mar 12, 2024NeedhamReiteratedBuyBuy
Mar 5, 2024RBC CapitalMaintainedOutperformOutperform
Feb 28, 2024HC Wainwright & Co.ReiteratedBuyBuy
Feb 28, 2024RBC CapitalMaintainedOutperformOutperform
Feb 28, 2024NeedhamReiteratedBuyBuy
Feb 5, 2024NeedhamMaintainedBuyBuy
Feb 5, 2024HC Wainwright & Co.MaintainedBuyBuy
Nov 10, 2023RBC CapitalMaintainedOutperformOutperform
Oct 4, 2023NeedhamReiteratedBuyBuy
Sep 27, 2023HC Wainwright & Co.MaintainedBuyBuy
Sep 27, 2023NeedhamReiteratedBuyBuy
Sep 15, 2023NeedhamReiteratedBuyBuy
Aug 29, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 22, 2023Cantor FitzgeraldReiteratedOverweightOverweight